Skip to main content

Table 1 Comparative adverse events of different DMTs [7, 8]

From: Decision making under uncertainty, therapeutic inertia, and physicians’ risk preferences in the management of multiple sclerosis (DIScUTIR MS)

Disease modifying agent

Adverse events

Interferon beta

• Depression

• thrombotic microangiopathy

• hepatotoxicity

• ISRs

• Flu-like

• LFT elevation

• Leukopenia

Glatiramer acetate

• ISRs

• Benign systemic reaction

Mitoxantrone

• Cardiac toxicity

• Leukemia

Natalizumab

• Infusion reactions

• PML

• Infusion-related fatigue

Fingolimod

• Bradyarrhythmia

• Macular edema

• Herpes virus infection

• PML

• BCC

• LFT elevation

• Lymphopenia

• Mild hypertension

Teriflunomide

• Hepatotoxicity

• Peripheral neuropathy

• Alopecia

• Nausea/Diarrhea

Dimethyl fumarate

• Flushing

• Gastrointestinal

• PML

Alemtuzumab

• Infusion reactions

• ITP

• Goodpasture syndrome

• Thyroid cancer

• Infections

• Autoimmune thyroid disease

  1. ISRs injection-site reactions, LFT liver function test, PML progressive multifocal leukoencephalopathy, ITP idiopathic thrombocytopenic purpura, BCC basal cell carcinoma